Four IPOs raised $767 million. Even as the broader IPO market traded off, all four companies this week were positive and three popped 40% or more. Big data software provider Elastic (ESTC) priced well above its range and flew up 94%. With...read more
Kodiak Sciences, a phase 1 biotech developing therapies for common ophthalmic diseases, raised $90 million by offering 9 million shares at $10, below the range of $13 to $15. Insiders purchased $58 million (64% of deal size) on the offering. At pricing, Kodiak...read more
Kodiak Sciences, a Phase 1 biotech developing anti-VEGF inhibitors for wet AMD, announced terms for its IPO on Monday. The Palo Alto, CA-based company plans to raise $126 million by offering 9.0 million shares at a price range of $13 to $15. Insiders...read more
Kodiak Sciences, a Phase 1 biotech developing antibody therapies to treat age-related macular degeneration, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Palo Alto, CA-based company was founded in 2009 and plans...read more
US IPO Weekly Recap: US tech IPOs on a tear as Elastic bounds 94%
Four IPOs raised $767 million. Even as the broader IPO market traded off, all four companies this week were positive and three popped 40% or more. Big data software provider Elastic (ESTC) priced well above its range and flew up 94%. With...read more
Kodiak Sciences prices IPO well below the range at $10
Kodiak Sciences, a phase 1 biotech developing therapies for common ophthalmic diseases, raised $90 million by offering 9 million shares at $10, below the range of $13 to $15. Insiders purchased $58 million (64% of deal size) on the offering. At pricing, Kodiak...read more
Macular degeneration biotech Kodiak Sciences sets terms for $126 million IPO
Kodiak Sciences, a Phase 1 biotech developing anti-VEGF inhibitors for wet AMD, announced terms for its IPO on Monday. The Palo Alto, CA-based company plans to raise $126 million by offering 9.0 million shares at a price range of $13 to $15. Insiders...read more
Macular degeneration biotech Kodiak Sciences files for a $100 million IPO
Kodiak Sciences, a Phase 1 biotech developing antibody therapies to treat age-related macular degeneration, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Palo Alto, CA-based company was founded in 2009 and plans...read more